LCK-targeting molecular glues overcome resistance to inhibitor-based therapy in T-cell acute lymphoblastic leukemia
Yang, J. J.; Nishiguchi, G.; Yoshimura, S.; Actis, M.; Seffernick, J. T.; Jarusiewicz, J. A.; Aggarwal, A.; Li, A.; Li, Y.; Lee, D.; Yang, L.; Mayasundari, A.; Rankovic, Z.; Fischer, M.
Show abstract
Drug resistance is a major challenge in cancer therapy, especially in the context of kinase inhibitors. While targeted protein degradation (TPD) was a distinct mode of action compared to inhibition-based therapeutic targeting, the potential value of TPD in drug-resistant cancer remains unclear. Here, we report the discovery of cereblon-recruiting molecular glue degraders (MGDs) targeting LCK, an oncogenic kinase in T-cell acute lymphoblastic leukemia (T-ALL). By high-throughput screening and medicinal chemistry optimization, we developed a series of MGDs that induced CRBN-dependent degradation of LCK as well as potent cytotoxicity in T-ALL in vitro. Structure-activity relationship analysis and ternary complex modeling revealed a non-canonical degron at the LCK-CRBN interface involving the G-loop, whose mutation disrupts this interaction. Unlike inhibitors and inhibitor-based PROTACs, these MGDs engage LCK in regions distal to the ATP binding site and thus their activities in T-ALL are not affected by gate-keeper LCK mutations that drive resistance to inhibitor-based therapeutics. Taken together, our data underscore the potential of LCK-targeting MGDs as a strategy to overcome kinase inhibitor resistance in T-ALL, highlighting a potentially generalizable strategy in cancer therapy.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Repurposing of the RIPK1 selective benzooxazepin-4-one scaffold for the development of a type-III LIMK1/2 inhibitor 96%
- A selective and rapid cell-permeable inhibitor of human caspase-3 94%
- Functional characterization of pathway inhibitors for the ubiquitin-proteasome system (UPS) as tool compounds for CRBN and VHL-mediated targeted protein degradation 94%
Similar papers in this journal
- Characterization of new highly selective pyrazolopyrimidine inhibitor of CDK7 94%
- As48, a First-in-Class Dual-Function TREM2 Modulator: Receptor Activation and Shedding Inhibition 92%
- Novel assays monitoring direct glucocorticoid receptor protein activity exhibit high predictive power for ligand activity on endogenous gene targets 91%
Similar papers in this journal
- Enhancing Intracellular Accumulation and Target Engagement of PROTACs with Reversible Covalent Chemistry 96%
- Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19 94%
- Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance 94%
Similar papers in this journal
- Structure-aided development of small molecule inhibitors of ENPP1, the extracellular phosphodiesterase of the immunotransmitter cGAMP 96%
- Catalytic domain plasticity of MKK7 reveals structural mechanisms of allosteric activation and new targeting opportunities 95%
- An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor. 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.